China Merchants China Direct Investments Limited (CMCDI, Stock Code: 133) disclosed that its wholly-owned subsidiary, Shenzhen Tian Zheng Investment Co., Ltd. (Tian Zheng), entered into a share purchase agreement and other relevant agreements on 28 October 2025. The agreements involve Neuracle Technology (Shanghai) Co., Ltd. (Neuracle Technology), a high-tech enterprise centered on proprietary brain-computer interface (BCI) technology.

According to the announcement, Tian Zheng agreed to commit RMB 15 million in Neuracle Technology’s Series E funding and completed this capital contribution on 7 November 2025. Founded in November 2011, Neuracle Technology specializes in the research, development, production, sales, and technical services of BCI systems. Its solutions support various domains, including neuroscience, psychology, and rehabilitation for neurological disorders.

The announcement states that this move increases CMCDI’s involvement in medical projects and further optimizes its investment portfolio.